eli lilly tirzepatide trial New clinical trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss Eli Lilly said its next-generation

This is a much newer and widely recognized medication

Great tool If youre a patient or provider whos been affected by the shortages or recently found supply, check out the tracker, contribute, and let us know your experience

Monitoring markers Practitioners using these protocols typically track several categories of markers to assess response

Understanding GLP-1 Receptor Agonists Glucagon-like peptide-1 (GLP-1) receptor agonists are medications that mimic the action of the natural GLP-1 hormone in your body

Experiencing increased cramping or changes in PMS (premenstrual syndrome) symptoms may also coincide with the use of semaglutide

Participants were excluded from the study if the received antidiabetic agents other than metformin